CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 220 enrolled
Drug / intervention
IVT PCV-25 Formulation A +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06077656
NCT06077656Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 25-Valent Pneumococcal Conjugate Vaccine in Healthy PCV-Naïve Adults

Inventprise Inc.·interventional·Posted Oct 11, 2023·Updated Mar 17, 2026

In Brief

A Phase 2 clinical trial evaluating IVT PCV-25 Formulation A, IVT PCV-25 Formulation B, and 2 other interventions for Pneumococcal Vaccines. Completed, enrolled 220 participants across 4 sites.

Detailed Summary

Phase 2 trial to evaluate safety, tolerability, and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Vaccines
CountriesCanada
CollaboratorsCanadian Center for Vaccinology, Vaccine Evaluation Center, Canada, PATH

Timeline

Phase 2CompletedFinished
202420252026
First PostedOct 11, 2023
Enrollment StartOct 25, 2023
Primary CompletionMay 24, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 2.7 years ago

Interventions

IVT PCV-25 Formulation Abiological

25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and low dose adjuvant

IVT PCV-25 Formulation Bbiological

25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and high dose adjuvant

IVT PCV-25 Formulation Cbiological

25 valent pneumococcal conjugate vaccine containing high dose polysaccharide and high dose adjuvant

PCV 20biological

20 valent pneumococcal conjugate vaccine